Underutilization of anthracyclines in the management of HER2-overexpressing advanced breast cancer patients

被引：0
|
作者：
Montemurro, F.
Redana, S.
Valabrega, G.
Donadio, M.
Jacomuzzi, M. E.
Vietti-Ramus, G.
Clavarezza, M.
Danese, S.
Durando, A.
Venturini, M.
Aglietta, M.
机构：
[1] Inst Canc Res & Treatment, Candiolo, Italy
[2] Molinette Mauriziano Hosp, Ctr Oncol Subalpino COES, Turin, Italy
[3] Mauriziano Hosp, Turin, Italy
[4] Giovanni Bosco Hosp, Turin, Italy
[5] Ist Nazl Tumori, Senol Dis Management Team, Genoa, Italy
[6] St Anna Hosp, Turin, Italy
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：XI9 / XI10
页数：2
相关论文
共 50 条
  • [21] Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
    Emde, Anna
    Koestler, Wolfgang J.
    Yarden, Yosef
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 84 : E49 - E57
  • [22] Influence of trastuzumab on the incidence of brain metastasis in patients with Her2-overexpressing metastatic breast cancer
    Massard, C.
    Brain, E.
    Dunan, A.
    Mathieu, M.
    Guinebretiere, J.
    Abuin, G. Gomez
    Floiras, J.
    Spielmann, M.
    Delaloge, S.
    Andre, F.
    EJC SUPPLEMENTS, 2005, 3 (02): : 119 - 120
  • [23] Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines
    Kosmas, Christos
    Tsavaris, Nicolas
    Malamos, Nikolaos
    Tsakonas, George
    Gassiamis, Argyris
    Polyzos, Aristidis
    Mylonakis, Nicolas
    Karabelis, Athanasios
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (05) : 463 - 470
  • [24] Meningeal carcinomatosis in HER2-overexpressing breast cancers
    F. C. Bidard
    M. N. Guilhaume
    H. Gauthier
    P. H. Cottu
    V. Diéras
    J. Y. Pierga
    Journal of Neuro-Oncology, 2009, 93 : 287 - 288
  • [25] Meningeal carcinomatosis in HER2-overexpressing breast cancers
    Bidard, F. C.
    Guilhaume, M. N.
    Gauthier, H.
    Cottu, P. H.
    Dieras, V.
    Pierga, J. Y.
    JOURNAL OF NEURO-ONCOLOGY, 2009, 93 (02) : 287 - 288
  • [26] Trastuzumab (Herceptin®): overcoming resistance in HER2-overexpressing breast cancer models
    Albrecht, Huguette
    IMMUNOTHERAPY, 2010, 2 (06) : 795 - 798
  • [27] Pyrotinib enhances the radiosensitivity of HER2-overexpressing gastric and breast cancer cells
    Huang, Tingting
    Luo, Xiaoxiao
    Wu, Bili
    Peng, Ping
    Dai, Yuhong
    Hu, Guangyuan
    Qiu, Hong
    Yuan, Xianglin
    ONCOLOGY REPORTS, 2020, 44 (06) : 2634 - 2644
  • [28] Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Kikuchi, M.
    Sato, A.
    Ishikawa, Y.
    Odawara, H.
    Iino, Y.
    Takeyoshi, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [29] The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer
    Dent, S.
    Verma, Sh.
    Latreille, J.
    Rayson, D.
    Clemons, M.
    Mackey, J.
    Verma, Su
    Lemieux, J.
    Provencher, L.
    Chia, S.
    Wang, B.
    Pritchard, K.
    CURRENT ONCOLOGY, 2009, 16 (04) : 235 - 245
  • [30] Differential expression of γKlotho in triple negative and Her2-overexpressing breast cancer
    Provatopoulou, X.
    Kalogera, E.
    Soupos, N.
    Karampelias, G.
    Aravantinos, G.
    Grigoropoulos, P.
    Gounaris, A.
    BREAST, 2017, 32 : S93 - S94
12345